Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort

Johan Burisch; Natalia Pedersen; Silvja Cukovic-Cavka; Niksa Turk; Ioannis Kaimakliotis; Dana Duricova; Olga Shonová; Ida Vind; Søren Avnstrøm; Niels Thorsgaard; Susanne Krabbe; Vibeke Andersen; Frederik Dahlerup Jens; Jens Kjeldsen; Riina Salupere; Jóngerð Olsen; Kári Rubek Nielsen; Pia Manninen; Pekka Collin; Konstantinnos H Katsanos; Epameinondas V Tsianos; Karin Ladefoged; Laszlo Lakatos; Yvonne Bailey; Colm O'Morain; Doron Schwartz; Selwyn Odes; Matteo Martinato; Silvia Lombardini; Laimas Jonaitis; Limas Kupcinskas; Svetlana Turcan; Louisa Barros; Fernando Magro; Daniela Lazar; Adrian Goldis; Inna Nikulina; Elena Belousova; Alberto Fernandez; Vicent Hernandez; Sven Almer; Yaroslava Zhulina; Jonas Halfvarson; Her-Hsin Tsai; Shaji Sebastian; Peter Laszlo Lakatos; Ebbe Langholz; Pia Munkholm; EpiCom Group

doi:10.1097/01.mib.0000436277.13917.c4

Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort

Johan Burisch, Natalia Pedersen, Silvja Cukovic-Cavka, Niksa Turk, Ioannis Kaimakliotis, Dana Duricova, Olga Shonová, Ida Vind, Søren Avnstrøm, Niels Thorsgaard, Susanne Krabbe, Vibeke Andersen, Frederik Dahlerup Jens, Jens Kjeldsen, Riina Salupere, Jóngerð Olsen, Kári Rubek Nielsen, Pia Manninen, Pekka Collin, Konstantinnos H KatsanosEpameinondas V Tsianos, Karin Ladefoged, Laszlo Lakatos, Yvonne Bailey, Colm O'Morain, Doron Schwartz, Selwyn Odes, Matteo Martinato, Silvia Lombardini, Laimas Jonaitis, Limas Kupcinskas, Svetlana Turcan, Louisa Barros, Fernando Magro, Daniela Lazar, Adrian Goldis, Inna Nikulina, Elena Belousova, Alberto Fernandez, Vicent Hernandez, Sven Almer, Yaroslava Zhulina, Jonas Halfvarson, Her-Hsin Tsai, Shaji Sebastian, Peter Laszlo Lakatos, Ebbe Langholz, Pia Munkholm, EpiCom Group

Department of Clinical Medicine

59 Citations (Scopus)

Abstract

BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort.

METHODS: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu).

RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe.

DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.

Original language	English
Journal	Inflammatory Bowel Diseases
Volume	20
Issue number	1
Pages (from-to)	36-46
Number of pages	11
ISSN	1078-0998
DOIs	https://doi.org/10.1097/01.mib.0000436277.13917.c4
Publication status	Published - Jan 2014

Keywords

Adolescent
Adult
Aged
Aged, 80 and over
Combined Modality Therapy
Databases, Factual
Disease Progression
Europe
Female
Follow-Up Studies
Humans
Incidence
Inflammatory Bowel Diseases
Male
Middle Aged
Prognosis
Prospective Studies
Remission Induction
Young Adult

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/01.mib.0000436277.13917.c4

https://academic.oup.com/ibdjournal/article-pdf/20/1/36/23404470/ibd0036.pdf

Cite this

Burisch, J., Pedersen, N., Cukovic-Cavka, S., Turk, N., Kaimakliotis, I., Duricova, D., Shonová, O., Vind, I., Avnstrøm, S., Thorsgaard, N., Krabbe, S., Andersen, V., Dahlerup Jens, F., Kjeldsen, J., Salupere, R., Olsen, J., Nielsen, K. R., Manninen, P., Collin, P., ... EpiCom Group (2014). Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort. Inflammatory Bowel Diseases, 20(1), 36-46. https://doi.org/10.1097/01.mib.0000436277.13917.c4

Burisch, J, Pedersen, N, Cukovic-Cavka, S, Turk, N, Kaimakliotis, I, Duricova, D, Shonová, O, Vind, I, Avnstrøm, S, Thorsgaard, N, Krabbe, S, Andersen, V, Dahlerup Jens, F, Kjeldsen, J, Salupere, R, Olsen, J, Nielsen, KR, Manninen, P, Collin, P, Katsanos, KH, Tsianos, EV, Ladefoged, K, Lakatos, L, Bailey, Y, O'Morain, C, Schwartz, D, Odes, S, Martinato, M, Lombardini, S, Jonaitis, L, Kupcinskas, L, Turcan, S, Barros, L, Magro, F, Lazar, D, Goldis, A, Nikulina, I, Belousova, E, Fernandez, A, Hernandez, V, Almer, S, Zhulina, Y, Halfvarson, J, Tsai, H-H, Sebastian, S, Lakatos, PL, Langholz, E, Munkholm, P & EpiCom Group 2014, 'Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort', Inflammatory Bowel Diseases, vol. 20, no. 1, pp. 36-46. https://doi.org/10.1097/01.mib.0000436277.13917.c4

@article{ba1a3ce57ce6495cb1efc4682df4bb7e,

title = "Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort",

abstract = "BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort.METHODS: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu).RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe.DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.",

keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Combined Modality Therapy, Databases, Factual, Disease Progression, Europe, Female, Follow-Up Studies, Humans, Incidence, Inflammatory Bowel Diseases, Male, Middle Aged, Prognosis, Prospective Studies, Remission Induction, Young Adult",

author = "Johan Burisch and Natalia Pedersen and Silvja Cukovic-Cavka and Niksa Turk and Ioannis Kaimakliotis and Dana Duricova and Olga Shonov{\'a} and Ida Vind and S{\o}ren Avnstr{\o}m and Niels Thorsgaard and Susanne Krabbe and Vibeke Andersen and {Dahlerup Jens}, Frederik and Jens Kjeldsen and Riina Salupere and J{\'o}nger{\dh} Olsen and Nielsen, {K{\'a}ri Rubek} and Pia Manninen and Pekka Collin and Katsanos, {Konstantinnos H} and Tsianos, {Epameinondas V} and Karin Ladefoged and Laszlo Lakatos and Yvonne Bailey and Colm O'Morain and Doron Schwartz and Selwyn Odes and Matteo Martinato and Silvia Lombardini and Laimas Jonaitis and Limas Kupcinskas and Svetlana Turcan and Louisa Barros and Fernando Magro and Daniela Lazar and Adrian Goldis and Inna Nikulina and Elena Belousova and Alberto Fernandez and Vicent Hernandez and Sven Almer and Yaroslava Zhulina and Jonas Halfvarson and Her-Hsin Tsai and Shaji Sebastian and Lakatos, {Peter Laszlo} and Ebbe Langholz and Pia Munkholm and {EpiCom Group}",

year = "2014",

month = jan,

doi = "10.1097/01.mib.0000436277.13917.c4",

language = "English",

volume = "20",

pages = "36--46",

journal = "Inflammatory Bowel Diseases",

issn = "1078-0998",

publisher = "Lippincott Williams & Wilkins",

number = "1",

}

TY - JOUR

T1 - Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe

T2 - The ECCO-EpiCom Cohort

AU - Burisch, Johan

AU - Pedersen, Natalia

AU - Cukovic-Cavka, Silvja

AU - Turk, Niksa

AU - Kaimakliotis, Ioannis

AU - Duricova, Dana

AU - Shonová, Olga

AU - Vind, Ida

AU - Avnstrøm, Søren

AU - Thorsgaard, Niels

AU - Krabbe, Susanne

AU - Andersen, Vibeke

AU - Dahlerup Jens, Frederik

AU - Kjeldsen, Jens

AU - Salupere, Riina

AU - Olsen, Jóngerð

AU - Nielsen, Kári Rubek

AU - Manninen, Pia

AU - Collin, Pekka

AU - Katsanos, Konstantinnos H

AU - Tsianos, Epameinondas V

AU - Ladefoged, Karin

AU - Lakatos, Laszlo

AU - Bailey, Yvonne

AU - O'Morain, Colm

AU - Schwartz, Doron

AU - Odes, Selwyn

AU - Martinato, Matteo

AU - Lombardini, Silvia

AU - Jonaitis, Laimas

AU - Kupcinskas, Limas

AU - Turcan, Svetlana

AU - Barros, Louisa

AU - Magro, Fernando

AU - Lazar, Daniela

AU - Goldis, Adrian

AU - Nikulina, Inna

AU - Belousova, Elena

AU - Fernandez, Alberto

AU - Hernandez, Vicent

AU - Almer, Sven

AU - Zhulina, Yaroslava

AU - Halfvarson, Jonas

AU - Tsai, Her-Hsin

AU - Sebastian, Shaji

AU - Lakatos, Peter Laszlo

AU - Langholz, Ebbe

AU - Munkholm, Pia

AU - EpiCom Group

PY - 2014/1

Y1 - 2014/1

N2 - BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort.METHODS: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu).RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe.DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.

AB - BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort.METHODS: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu).RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe.DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Combined Modality Therapy

KW - Databases, Factual

KW - Disease Progression

KW - Europe

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Incidence

KW - Inflammatory Bowel Diseases

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Prospective Studies

KW - Remission Induction

KW - Young Adult

U2 - 10.1097/01.mib.0000436277.13917.c4

DO - 10.1097/01.mib.0000436277.13917.c4

M3 - Journal article

C2 - 24252978

SN - 1078-0998

VL - 20

SP - 36

EP - 46

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

IS - 1

ER -

Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this